Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer's Disease

被引：7

作者：

Hampel, H. ^{[1
,2
,3
,4
,5
,7
,8
]}

Vergallo, A. ^{[1
,2
,3
,4
,5
]}

Bonuccelli, U. ^{[6
]}

Lista, S. ^{[1
,2
,3
,4
,5
]}

机构：

[1] AXA Res Fund, 47 Blvd Hop, F-75651 Paris 13, France

[2] Sorbonne Univ, Paris, France

[3] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, GRC 21,APM, Blvd Hop, F-75013 Paris, France

[4] INSERM, CNRS, U1127, UMR 7225,Brain & Spine Inst ICM, Blvd Hop, F-75013 Paris, France

[5] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Inst Memory & Alzheimers Dis IM2A, Blvd Hop, F-75013 Paris, France

[6] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

[7] Sorbonne Univ, Clin Res Grp GRC 21, APM, Etab Publ Caractere Sci & Technol EPST,APMI, Paris, France

[8] Sorbonne Univ, CSWG, Paris, France

来源：

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE | 2018年 / 5卷 / 03期

关键词：

FLUID BARRIER DYSFUNCTION; MAJOR DEPRESSION; DISCOVERY; DEMENTIA;

D O I：

10.14283/jpad.2018.25

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：160 / 164

页数：5

共 14 条

[1] Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease [J].

Aisen, Paul S. ;

Vellas, Bruno ;

Hampel, Harald .

NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (04) :325-326

[2] Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force [J].

Cummings, J. ;

Fox, N. ;

Vellas, B. ;

Aisen, P. ;

Shan, G. ;

Cosma-Roman, D. ;

Dekosky, S. ;

Delrieu, J. ;

Donohue, M. ;

Dube, S. ;

Dubois, B. ;

Frisoni, G. ;

Fullerton, T. ;

Gauthier, S. ;

Goedkoop, R. ;

Grundman, M. ;

Guthrie, S. ;

Ho, C. ;

Tome, M. ;

Lawson, J. ;

Lovestone, S. ;

Lyketsos, C. ;

Malamut, R. ;

Merdes, A. ;

Mintzer, J. ;

Molinuevo, J. L. ;

Olsson, T. ;

Ousset, P. J. ;

Peskind, E. ;

Pollentier, S. ;

Porteinsson, A. ;

Pueyo, M. ;

Rafii, M. ;

Raman, R. ;

Rosenberg, P. ;

Rouru, J. ;

Rubino, I ;

Solloway, S. ;

Scheltens, P. ;

Siemers, E. ;

Siffert, J. ;

Sims, J. ;

Smith, J. ;

Sperling, B. ;

Sperling, R. ;

Touchon, J. ;

Van der Geyten, S. ;

Weiner, M. ;

Wilcock, G. .

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2018, 5 (02) :103-109

[3] Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children [J].

Drilon, A. ;

Laetsch, T. W. ;

Kummar, S. ;

DuBois, S. G. ;

Lassen, U. N. ;

Demetri, G. D. ;

Nathenson, M. ;

Doebele, R. C. ;

Farago, A. F. ;

Pappo, A. S. ;

Turpin, B. ;

Dowlati, A. ;

Brose, M. S. ;

Mascarenhas, L. ;

Federman, N. ;

Berlin, J. ;

El-Deiry, W. S. ;

Baik, C. ;

Deeken, J. ;

Boni, V. ;

Nagasubramanian, R. ;

Taylor, M. ;

Rudzinski, E. R. ;

Meric-Bernstam, F. ;

Sohal, D. P. S. ;

Ma, P. C. ;

Raez, L. E. ;

Hechtman, J. F. ;

Benayed, R. ;

Ladanyi, M. ;

Tuch, B. B. ;

Ebata, K. ;

Cruickshank, S. ;

Ku, N. C. ;

Cox, M. C. ;

Hawkins, D. S. ;

Hong, D. S. ;

Hyman, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) :731-739

[4] Oligoclonal bands and blood-cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease:: Comparison with vascular dementia, major depression, and multiple sclerosis [J].

Hampel, H ;

Kötter, HU ;

Padberg, F ;

Körschenhausen, DA ;

Möller, HJ .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1999, 13 (01) :9-19

[5]

Hampel H, 2016, J Prev Alzheimers Dis, V3, P243, DOI 10.14283/jpad.2016.112

[6] A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling [J].

Hampel, H. ;

O'Bryant, S. E. ;

Durrleman, S. ;

Younesi, E. ;

Rojkova, K. ;

Escott-Price, V. ;

Corvol, J-C. ;

Broich, K. ;

Dubois, B. ;

Lista, S. .

CLIMACTERIC, 2017, 20 (02) :107-118

[7] Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: Indication for disease subsets [J].

Hampel, H ;

Kotter, HU ;

Moller, HJ .

ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1997, 11 (02) :78-87

[8] EVIDENCE OF BLOOD CEREBROSPINAL FLUID-BARRIER IMPAIRMENT IN A SUBGROUP OF PATIENTS WITH DEMENTIA OF THE ALZHEIMER-TYPE AND MAJOR DEPRESSION - A POSSIBLE INDICATOR FOR IMMUNOACTIVATION [J].

HAMPEL, H ;

MULLERSPAHN, F ;

BERGER, C ;

HABERL, A ;

ACKENHEIL, M ;

HOCK, C .

DEMENTIA, 1995, 6 (06) :348-354

[9] Precision pharmacology for Alzheimer's disease [J].

Hampel, Harald ;

Vergallo, Andrea ;

Aguilar, Lisi Flores ;

Benda, Norbert ;

Broich, Karl ;

Cuello, A. Claudio ;

Cummings, Jeffrey ;

Dubois, Bruno ;

Federoff, Howard J. ;

Fiandaca, Massimo ;

Genthon, Remy ;

Haberkamp, Marion ;

Karran, Eric ;

Mapstone, Mark ;

Perry, George ;

Schneider, Lon S. ;

Welikovitch, Lindsay A. ;

Woodcock, Janet ;

Baldacci, Filippo ;

Lista, Simone .

PHARMACOLOGICAL RESEARCH, 2018, 130 :331-365

[10] Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology [J].

Hampel, Harald ;

Toschi, Nicola ;

Babiloni, Claudio ;

Baldacci, Filippo ;

Black, Keith L. ;

Bokde, Arun L. W. ;

Bun, Ren Prime E. S. ;

Cacciola, Francesco ;

Cavedo, Enrica ;

Chiesa, Patrizia A. ;

Colliot, Olivier ;

Coman, Cristina-Maria ;

Dubois, Bruno ;

Duggento, Andrea ;

Durrleman, Stanley ;

Ferretti, Maria-Teresa ;

George, Nathalie ;

Genthon, Remy ;

Habert, Marie-Odile ;

Herholz, Karl ;

Koronyo, Yosef ;

Koronyo-Hamaoui, Maya ;

Lamari, Foudil ;

Langevin, Todd ;

Lehericy, Stephane ;

Lorenceau, Jean ;

Neri, Christian ;

Nistico, Robert ;

Nyasse-Messene, Francis ;

Ritchie, Craig ;

Rossi, Simone ;

Santarnecchi, Emiliano ;

Sporns, Olaf ;

Verdooner, Steven R. ;

Vergallo, Andrea ;

Villain, Nicolas ;

Younesi, Erfan ;

Garaci, Francesco ;

Lista, Simone .

JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 :S47-S105

← 1 2 →